Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review

MenACWY-TT (Nimenrix ® ) is a quadrivalent meningococcal tetanus toxoid conjugate vaccine licensed in Europe for active immunisation of individuals aged ≥ 6 weeks against invasive disease caused by Neisseria meningitidis capsular groups A, C, W and Y. MenACWY-TT is the first quadrivalent conjugate v...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2017-11, Vol.77 (17), p.1881-1896
Main Authors: Dhillon, Sohita, Pace, David
Format: Article
Language:English
Subjects:
Adis Drug Evaluation
Age
Disease
Epidemiology
Immune system
Immunogenicity
Immunology
Infants
Internal Medicine
Medicine
Medicine & Public Health
Neisseria meningitidis
Pharmacology/Toxicology
Pharmacotherapy
Proteins
Public health
Teenagers
Tetanus
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MenACWY-TT (Nimenrix ® ) is a quadrivalent meningococcal tetanus toxoid conjugate vaccine licensed in Europe for active immunisation of individuals aged ≥ 6 weeks against invasive disease caused by Neisseria meningitidis capsular groups A, C, W and Y. MenACWY-TT is the first quadrivalent conjugate vaccine to be approved in Europe for use in infants as young as 6 weeks of age. Numerous phase II–IIIb clinical studies showed that intramuscular MenACWY-TT administered as primary or booster vaccination was highly immunogenic for all four vaccine capsular groups and had an acceptable reactogenicity profile in individuals aged 6 weeks to ≥ 56 years. MenACWY-TT is as immunogenic and safe as other previously licensed monovalent capsular group C or quadrivalent capsular groups A, C, W and Y meningococcal vaccines and can be coadministered with other routine vaccines without adversely affecting the immunogenicity or safety profiles of either vaccine. Current data indicate that primary and booster vaccination with MenACWY-TT is a valuable and safe option for broadening meningococcal protection against four capsular groups across a broad age range, starting as early as 6 weeks of age.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-017-0828-8